- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00330499
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Whilst concurrent chemo-radiation is increasingly being looked upon as the treatment of choice for patients referred for bladder preservation, the study by the NCI of Canada (Coppin CM, Gospodarowicz MK et al.Improved Local Control of Invasive Bladder Cancer by Concurrent Cisplatin and Pre-operative or Definitive Radiation.J. of Clinical Oncol. 14(11): 2901-2907, 1996) is the only randomised trial to show some superiority of concurrent Cisplatin and radiation treatment over radiation alone in increasing pelvic tumour control. There was no impact on overall survival. However, this study had relatively small subject numbers and included two distinct treatment options. In one group the patients were treated with a bladder sparing approach and in the other by pre-operative therapy and cystectomy with the type of definitive treatment being decided upon by both the treating Specialist and patient. At 5 years the pelvic failure rates in the radiation alone and chemo-radiation arms were 59% and 40% respectively. With half of the patients in each group having had planned cystectomy as part of their treatment regimen, the above rates of local relapse (especially in the chemo-radiation arm) are disappointing.
Given the concerns with the above study, and the continuing paucity of randomised phase III studies comparing chemo-radiation with radiation alone, there lies an opportunity for Australasian centres to take up the challenge. For this study, the proposed schedule for the chemo-radiation arm is to be the same as that being investigated in our previous phase II study (six weekly doses of Cisplatin plus radiation to a dose of 64Gy in 32 fractions over 6.5 weeks). This will be compared with radical radiation alone (64Gy in 32 fractions over 6.5 weeks).
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 1871
- Liverpool Hospital
-
Newcastle, New South Wales, Australia, 2298
- Calvary Mater Newcastle
-
Penrith, New South Wales, Australia, 2751
- Nepean Cancer Care Centre
-
Randwick, New South Wales, Australia, 2031
- Prince of Wales Hospital
-
Wentworthville, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Queensland
-
Brisbane, Queensland, Australia, 4120
- Mater Centre - South Brisbane
-
Douglas, Queensland, Australia, 4814
- Townsville Hospital
-
Herston, Queensland, Australia, 4029
- Royal Brisbane Hospital
-
Tugun, Queensland, Australia, 4224
- East Coast Cancer Centre
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Tasmania
-
Launceston, Tasmania, Australia, 7250
- Launceston General Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Peter MacCallum Cancer Centre
-
Geelong, Victoria, Australia, 3220
- Andrew Love Cancer Care Centre, Geelong Hospital
-
Prahran, Victoria, Australia, 3181
- Alfred Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
-
Auckland, Nowa Zelandia, 1001
- Auckland Hospital
-
Christchurch, Nowa Zelandia, 4710
- Christchurch Hospital
-
Dunedin, Nowa Zelandia
- Dunedin Hospital
-
Palmerston North, Nowa Zelandia
- Palmerston North Hospital
-
Wellington, Nowa Zelandia, 7902
- Wellington Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Histologically proven TCC of the urinary bladder. Mixed tumours comprising predominantly TCC and elements of squamous or adenomatous metaplasia or carcinoma are also eligible.
- Clinically and radiologically localised T2, T3 or T4a non-bulky disease (<= 7cm in maximum dimension), N0, M0.
If radiological evaluation of a lymph node is interpreted as "positive" this must be evaluated further by either lymph node sampling or percutaneous needle biopsy. Patients with histologically confirmed lymph node metastases will not be eligible.
- Maximal TUR.
N.B. Previous:
- partial cystectomy;
- endoscopic resection of bladder tumour/s;
- intravesical chemotherapy; or
- intravesical BCG
does not exclude the patient from being eligible. However, the patient should have an adequate functioning bladder (this should be clarified with the referring Urologist and if need be voiding volumes should be measured).
- Creatinine clearance >= 50ml/minute by calculation or measurement.
- A white blood cell count >= 3.5 x 10^9/L with an absolute neutrophil count >= 1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.
- ECOG status of 0, 1 or 2.
- No age limit applies provided the patient is mentally, physically and geographically capable of undergoing treatment and follow-up.
- No significant intercurrent morbidity.
Exclusion Criteria:
- Pure squamous carcinomas or adenocarcinomas.
- Extensive or multifocal CIS change in the bladder.
- T3 or T4a tumours unsuitable for curative treatment (i.e. > 7cm in any dimension), T4b, node positive and metastatic disease.
- Presence of ureteric obstruction due to tumour infiltration at the UO not amenable to stenting.
- Previous radiation treatment to the pelvis.
- Previous significant pelvic surgery.
- Significant bowel or gynaecological inflammatory disease.
- Creatinine clearance < 50ml/minute by calculation or measurement. A white blood cell count < 3.5 x 10^9/L with an absolute neutrophil count < 1.5 x 10^9L and/or a platelet count < 100 x 10^9/L.
- Other considerations making patient unfit for Cisplatin therapy.
Prior or concurrent malignancy of any other site unless disease-free for greater than 5 years, except for:
- non-melanoma skin cancer, and/or
- (a) Stage T1 well differentiated prostatic carcinoma in men, and In situ carcinoma of the cervix in women.
- Bladder tumour - biopsy only. These patients must be referred back for more adequate resections or else should not be included
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: A
Synchronous chemo / radiation therapy
|
Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
Inne nazwy:
64Gy reference dose in 32 fractions over 6.5 weeks
Inne nazwy:
|
Aktywny komparator: B
Radiation Alone
|
64Gy reference dose in 32 fractions over 6.5 weeks
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Invasive local failure at 3 years
Ramy czasowe: 3 years
|
3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Complete response (CR) rate at 3 months from randomisation
Ramy czasowe: 3 months
|
3 months
|
Disease-free survival
Ramy czasowe: Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Overall survival
Ramy czasowe: Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Cystectomy-free survival
Ramy czasowe: Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Acute and late toxicity
Ramy czasowe: Interim analyses will be performed on an annual basis.
|
Interim analyses will be performed on an annual basis.
|
Pattern of failure (local, regional, distant)
Ramy czasowe: Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Quality of life measures
Ramy czasowe: Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Final analysis when all patients have been followed for 3 years. (approx. 7 years from start of trial)
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Krzesło do nauki: Kumar Gogna, Mater Centre - South Brisbane
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według typu histologicznego
- Nowotwory
- Nowotwory urologiczne
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Choroby Urologiczne
- Rak
- Nowotwory gruczołowe i nabłonkowe
- Choroby Pęcherza Moczowego
- Nowotwory pęcherza moczowego
- Rak, komórka przejściowa
- Środki przeciwnowotworowe
- Cisplatyna
Inne numery identyfikacyjne badania
- TROG 02.03
- NHMRC 243100
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .